Analysis by Disease (Human Immunodeficiency Virus, Herpes Simplex Virus, Human Papillomavirus, Chlamydia, Syphilis, Gonorrhea, Cancroid and Others); by Location (Laboratory, and Point of Care); and by Device (Laboratory Devices, and Point of Care Devices) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033
Buy Now
The global sexually transmitted disease testing market is estimated to garner a revenue of ~USD 145 billion by the end of 2033 by growing at a CAGR of ~6% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 95 billion in the year 2022. An increase in cases of sexually transmitted diseases (STDs) in the younger adult population, followed by unprotected sex and a lower level of awareness about safe sex in younger adults, are expected to increase the transmission of diseases. Hence, it is anticipated to boost the growth of the global sexually transmitted disease testing market. As per the data reported, every 1 in 4 teens gets infected by STD every year around the globe.
Get more information on this report:Download Sample PDF
The rise in sexual crimes against women has accelerated the transmission of sexually transmitted infections among women. Rape, sexual molestation, and assault against women are expected to increase sexually transmitted diseases, which are projected to bring lucrative growth opportunities. According to the United Nations, globally, 736 million women, at least once in their lifetime have experienced sexual intimate partner violence, non-partner violence, or both. Furthermore, a higher number of people working as sex workers, insurance covering the treatment of STDs, and increased cases of STDs are propelling the growth of the global sexually transmitted disease testing market. Moreover, HIV remains a significant public health concern around the world. Therefore, the goal of testing is to identify individuals that are suffering from the STD, so that it cannot be transferred to a healthy person. In the United Kingdom, for instance, the National Chlamydia Screening Program (NCSP) was launched in March 2022. The project's primary objective is to decrease the threat of undiagnosed chlamydia infection.
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~6% |
|
Base Year Market Size (2022) |
~ USD 95 Billion |
|
Forecast Year Market Size (2033) |
~ USD 145 Billion |
|
Regional Scope |
|
Insurance Policy for STD Testing and Treatment - In many cases, health insurance companies offer urgent care STD testing. As a result, patients with limited financial resources are expected to benefit from these policies, which are estimated to contribute to market growth. For instance, the Affordable Care Act (ACA) requires that most private insurance plans and public health coverage projects, such as Medicaid, encompass STI screening and counseling at no cost.
Rise in Global Population of Young Adults - Young adults are generally more curious, both sexually and socially active. As a result, their broadened mentality leads them to engage sexually with more partners, therefore, they are more susceptible to STDs. This trend is expected to fuel the market’s growth over the forecast period. By the statistics of the WHO, globally one in 20 young people catches STD each year. The rate is higher among the age group of 20-24 years.
Alarming Elevation in the Number of Rape Cases and Sexual Harassment - According to the WHO, every 1 in 3 women experience sexual violence at least once in their lifetime worldwide.
Rising Prevalence of Sexually Transmitted Disease (STD) - Cases of sexually transmitted is rising owing to people's active sexual life, choices of multiple partners and not using contraceptives. According to a World Health Organization report released in November 2021, over 1.0 million sexually transmitted infections are obtained globally, with the majority of them being asymptomatic. It also stated that approximately 374.0 million new infections with one of four sexually transmitted infections occurring annually: gonorrhea, chlamydia, trichomoniasis, and syphilis. As a consequence of the growing frequency and prevalence rate of sexually transmitted diseases around the world, the requirement for STD diagnostics is anticipated to rise, expanding market growth during the forecast period.
The global sexually transmitted disease testing market is segmented and analyzed for demand and supply by disease into human immunodeficiency virus, herpes simplex virus, human papillomavirus, chlamydia, syphilis, gonorrhea, cancroid, and others. Out of these, the chlamydia segment is expected to garner the highest revenue by the end of 2033. This can be attributed to the higher instances of chlamydia in the younger population owing to unprotected sex and in adults owing to involvement with different partners. Furthermore, there has been surging awareness related to chlamydia treatment, that is further predicted to boost the segment’s growth in the market. According to the World Health Organization, in 2020 there was nearly 129 million instances of chlamydia around the world. The Center for Disease Control and Prevention reported a total of 1,808,703 cases of chlamydia in 2019.
The market is segmented by location into laboratory and point of care. Out of these, the laboratory segment is expected to garner highest revenue, as laboratories are the most commonly used place for assessing Sexually Transmitted Diseases (STDs) worldwide. The blood screening is performed in laboratories with proper care in order to give correct results, and it is predicted to surge the segment’s growth in the market. Moreover, laboratory tests are precise and trustworthy, their use is widespread, and people place more faith in them, that is further anticipated to surge the segment’s growth in the market. Abbott laboratories provide an in vitro reverse transcription-polymerase chain reaction (RT-PCR) test and an in vitro polymerase chain reaction (PCR) assay for the identification of sexually transmitted diseases induced by Chlamydia trachomatis, Trichomonas vaginalis, and Mycoplasma genitalium, including gonorrhea. Correspondingly, Qiagen Inc. offers a diverse selection of screening test kits, along with STI assessments for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections with significant clinical sensitiveness and specificity, that are utilized to identify a variety of sexually transmitted diseases. More product introductions enable laboratories to configure devices or machinery as needed. For instance, with European Commission authorization, Qiagen Inc. released the NeuMoDxHSV 1/2 Quant Test for the measurement and distinction of herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2) in May 2022. These factors, as a result, are anticipated to create numerous opportunities for the growth of the segment in the coming years.
The Asia Pacific sexually transmitted disease testing market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. This can be attributed to the rising crimes related to sexual harassment in the region are increasing the chances of sexually transmitted disease along with the rising population, and the lack of sex education. In 2021, nearly 86 daily rapes and around 50 sexual crimes against women have been reported every hour in India. Moreover, in Thailand, the population of sex workers is around 250,000 to 2 million. Additionally, in 2021, over 20,000 deaths were caused by STDs in China, and nearly 20 thousand people died of AIDS.
On the other hand, the North America region is also expected to have a fastest growth owing to the increased incidence of STDs in the region. Moreover, there has been rising number of a substantial of clinical organizations and increased disease consciousness, that is anticipated to drive the market’s growth in the North American region. A survey released in April 2022 by the Centers for Disease Control and Prevention (CDC) titled "Sexually Transmitted Disease Surveillance, 2020" asserted that STDs persist as a major public health issue in the nation. Based on the same source, Chlamydia trachomatis disease was the highest common reportable sexually transmitted infection in the United States in 2020, with 1,579,885 people infected as per the CDC.
Our in-depth analysis of the global sexually transmitted disease testing market includes the following segments:
|
By Disease |
|
|
By Location |
|
|
By Device |
|
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: Rising cases of STD, sexual harassment, reimbursement schemes for STD testing and treatment and rising population of young adults are few factors likely to drive the market growth.
Ans: The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2023 – 2033.
Ans: Possibility of negative impact on the environment, disrupted supply chain owing to COVID-19, and lack of awareness and proper investment are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the Asia Pacific region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.
Ans: The major players in the market are F. Hoffmann-La Roche Ltd., Abbott, bioMerieux, Becton Dickinson and Company, Quest Diagnostics, Thermo Fisher Scientific, Hologic Inc., Orasure Technologies, Inc., S&P Global, DiaSorin Molecular LLC., and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by disease, location, device, and by region.
Ans: The laboratory segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
